Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD25 CAR-NK92
- Development stage
- Preclinical
- Lead developer
- Inserm
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal
01
Overview
CD25 CAR-NK92 is an experimental third-generation chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting the interleukin-2 receptor alpha chain (CD25/IL2RA). Developed by researchers at Inserm and the University of Paris Saclay, the therapy utilizes the NK92 cell line engineered with a CAR construct derived from the scFv of the monoclonal antibody basiliximab. CD25 is overexpressed in chronic myeloid leukemia (CML) during progression to blast crisis and in certain acute leukemias. Preclinical studies demonstrate that CD25 CAR-NK92 cells exhibit specific cytotoxicity, increased degranulation, and interferon-gamma release when exposed to CD25-positive leukemia cells, showing significant anti-leukemic activity in mouse models.
- Other names
- CD25-CAR-NK92CD-25-CAR-NK92CD 25-CAR-NK92Basiliximab-based CAR-NK92
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on CD25 CAR-NK92.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD25 CAR-NK92.